DALI PHARMACEUTICAL(SH:603963)2025-01-09 10:35Financial Performance Expectations - The company expects a total profit for 2024 to be between -26 million and -32 million RMB, with a net profit attributable to shareholders of -30 million to -36 million RMB[3]. - The estimated operating revenue for 2024 is projected to be between 62 million and 74 million RMB, significantly below the 300 million RMB threshold[3]. - The previous year's total profit was -17.37 million RMB, with a net profit attributable to shareholders of -20.03 million RMB[7]. - The operating revenue for the previous year was 87.27 million RMB, with adjusted revenue of 86.41 million RMB after excluding unrelated business income[7]. Product Performance and Challenges - The company's main product, Xinaojing injection, experienced a significant price drop of 61.05%, severely impacting profit margins and sales performance[8]. - The company has struggled to expand its pharmaceutical distribution business due to its small scale and limited authorization from upstream manufacturers[8]. Financial Risks and Warnings - The company has been under delisting risk warning since April 29, 2024, due to negative financial indicators[3]. - The company warns that if the audited financial results for 2024 show negative values, it may face termination of its stock listing[10]. - The financial data provided is preliminary and subject to change upon final audit[10]. Asset Projections - The net assets at the end of 2024 are expected to be between 340 million and 356 million RMB[6].